

## Efficacy and safety of SGLT2 inhibitor therapy in overweight and obese subjects with cystic fibrosis-related diabetes: a pilot study

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- 18 years or older - diagnosis of cystic fibrosis related diabetes (CFRD) - BMI >25 kg/m<sup>2</sup> - woman who could become pregnant must agree to take precautions that are effective in preventing pregnancy throughout this study

---

**Exclusion Criteria:**

- acute respiratory exacerbation requiring IV antibiotics or systemic glucocorticoids within prior 4 weeks - less than 12 weeks since start of a new CFTR corrector/modulator therapy - type 1 diabetes - history of diabetic ketoacidosis - history of recurrent genital or urinary tract infections - women who are pregnant or breastfeeding - history of eating disorder - there are additional exclusion criteria (study staff will review)

### Conditions & Interventions

**Conditions:**

Rare Diseases, Diabetes & Endocrine

**Keywords:**

CF, CFRD, Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Diabetes

### More Information

**Description:** In this study, we will examine the safety and tolerability of Sodium glucose co-transporter 2 inhibitor (SGLT2i) (generic name: empagliflozin) for patients who are overweight/obese and have been diagnosed with Cystic Fibrosis Related Diabetes (CFRD).

**Study Contact:** Catherine Larson - [sund0033@umn.edu](mailto:sund0033@umn.edu)

**Principal Investigator:** Amir Moheet

**IRB**

**Number:** STUDY00019241

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.